Inhibition of EGFR phosphorylation by erlotinib (Fig EV1D) induced tumor stasis indicated by significantly reduced tumor number, tumor size, and ALP serum levels, when compared to vehicle‐treated controls (Fig 1E–H). Here, EGFR is linked to neoplasm.